HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE)
This important study, called HAELO, is looking for people with Hereditary Angioedema (HAE) to test a new medicine named NTLA-2002. HAE is a condition that causes swelling attacks. The main goal is to find out if NTLA-2002 can effectively prevent these attacks and if it's safe to use. Some participants will receive the new medicine, while others will get a placebo (a treatment with no active drug) to help doctors understand the true effects of NTLA-2002. This study is ‘double-blind,’ meaning neither you nor your study doctor will know which treatment you are receiving at first. This helps ensure fair results. The study will involve a single infusion of the medicine and then careful monitoring over a long period.
Auf einen Blick
Worum geht es in dieser Studie?
This study, called HAELO, is designed to understand if a new medicine, NTLA-2002, can effectively help people who have a condition called Hereditary Angioedema (HAE). HAE causes sudden, unpredictable swelling attacks in different parts of the body, which can be very painful and even dangerous. Scientists believe NTLA-2002 might be able to reduce how often and how severe these attacks are.
The study aims to compare NTLA-2002 with a placebo. A placebo is like a dummy treatment that doesn't contain any active medicine. This comparison is important because it helps researchers work out if any changes in your HAE attacks are truly due to the new medicine or if they might happen anyway. About 60 people with HAE will take part in this study across different countries.
After an initial period, if you started on the dummy medicine, you'll have the option to receive the actual study medicine, and vice-versa. Everyone involved will be monitored for quite a long time – over two years in total – to carefully check both the effects of the medicine and how safe it is. This careful and thorough approach helps ensure that any new treatment is well understood before it becomes widely available.
Wichtige Erkenntnisse
- This study is testing a new medicine (NTLA-2002) for Hereditary Angioedema (HAE).
- It aims to see if NTLA-2002 can reduce HAE attacks and if it's safe.
- Participants will receive a single infusion – either the new medicine or a placebo.
- The study lasts over two years with regular check-ups.
- It's 'double-blind,' meaning you won't know which treatment you get at first.
- Only people aged 16 and over with specific types of HAE can join.
Wer könnte berechtigt sein?
To join this study, you need to be at least 16 years old and have a confirmed diagnosis of Hereditary Angioedema (HAE) – specifically Type 1 or Type 2. You’ll also need to be able to show your study doctor that you've been having HAE attacks that meet the study's requirements. It's important that you are able to take your usual emergency medicines if you have an HAE attack during the study, and your doctor must agree it's safe for you to stop your regular long-term preventative HAE medicines for the first few months of the study.
There are a few reasons why you might not be able to join. For example, if you have another type of swelling condition that isn't HAE, or if you've had a known bad reaction to certain fat-based particles (called lipid nanoparticles) that are used in the study medicine. Also, if your doctor believes that taking part in the study might not be safe for you because of another health condition, or if you can't commit to following all the study steps, you wouldn't be able to participate.
All participants must also agree not to join any other studies where you're trying out a new treatment for the whole time you're in this study. If you're 16 or 17, your parent or guardian will need to give their permission for you to join, and you'll also need to agree yourself.
Könnte diese Studie für Sie geeignet sein?
Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.
- Sind Sie 16 Jahre alt oder älter?
- Do you have Type 1 or Type 2 Hereditary Angioedema?
- Are you able to use your emergency HAE medicine if needed?
- Can you agree to temporarily stop your regular long-term preventative HAE medicines if your doctor says it's safe?
- Are you willing to commit to regular clinic visits and follow study procedures for about 28 months?
Was beinhaltet die Teilnahme?
If you decide to take part in this study, you'll first go through a screening period to make sure it's safe and right for you. If you qualify, you'll be randomly assigned to either receive the new medicine, NTLA-2002, or a placebo (a dummy medicine). You will receive this treatment as a single infusion into a vein (like a drip) in your arm.
For the first 28 weeks after your infusion, you'll be closely monitored. During this time, neither you nor your study doctor will know whether you received the active medicine or the placebo. After these 28 weeks, you'll have the option to receive an infusion of the opposite treatment from what you received initially, still without knowing which one you're getting.
Following this, you'll enter a long-term observation period for another 76 weeks. This means the study will involve regular visits to the clinic for assessments, blood tests, and to discuss any HAE attacks you might have. You'll need to use your regular emergency HAE medicines if you have an attack. In total, from the very beginning to the very end, your participation in the study will last for about 28 months (over two years).
Potenzielle Risiken und Vorteile
Standorte (29)
- Medical Research of ArizonaVerifizierte PostleitzahlScottsdale, Vereinigte Staaten
- University of California, San Diego (UCSD)Verifizierte PostleitzahlSan Diego, Vereinigte Staaten
- Raffi Tachdjian MD, IncVerifizierte PostleitzahlSanta Monica, Vereinigte Staaten
- Allergy & Asthma Clinical ResearchVerifizierte PostleitzahlWalnut Creek, Vereinigte Staaten
- IMMUNOe International Research CentersVerifizierte PostleitzahlCentennial, United States
- Asthma & Allergy AssociatesVerifizierte PostleitzahlColorado Springs, United States
- University of South FloridaVerifizierte PostleitzahlTampa, Vereinigte Staaten
- Massachusetts General HospitalVerifizierte PostleitzahlBoston, Vereinigte Staaten
- Washington University in St. LouisVerifizierte PostleitzahlSt. Louis, Vereinigte Staaten
- NYU Langone Health - Long IslandVerifizierte PostleitzahlMineola, United States
- Icahn School of Medicine am Mount SinaiVerifizierte PostleitzahlNew York, Vereinigte Staaten
- Bernstein Clinical Research Center, LLCVerifizierte PostleitzahlCincinnati, Vereinigte Staaten
Häufige Fragen
What is Hereditary Angioedema (HAE)?
HAE is a rare genetic condition that causes unpredictable episodes of swelling in different parts of the body, such as hands, feet, face, and airways.
What does 'single IV infusion' mean?
It means the study medicine will be given to you only once, directly into a vein, like a drip you might receive at a hospital.
Was ist ein 'Placebo'?
A placebo is an inactive substance or treatment that looks exactly like the real medicine but does not contain any active drug. It helps researchers compare the true effects of the new medicine.
Werde ich wissen, ob ich das echte Medikament oder das Placebo erhalte?
For the main part of the study, neither you nor your study doctor will know which treatment you are receiving. This is called 'double-blind' and helps keep the study fair.
Wie lange werde ich an der Studie teilnehmen?
If you join, your total time in the study will be about 28 months, which is just over two years.
Wie Sie mehr erfahren können
Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.
Diskussion
Community-Diskussion
Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.